CA2261703A1 - Electroporation employing user-configured pulses - Google Patents

Electroporation employing user-configured pulses Download PDF

Info

Publication number
CA2261703A1
CA2261703A1 CA002261703A CA2261703A CA2261703A1 CA 2261703 A1 CA2261703 A1 CA 2261703A1 CA 002261703 A CA002261703 A CA 002261703A CA 2261703 A CA2261703 A CA 2261703A CA 2261703 A1 CA2261703 A1 CA 2261703A1
Authority
CA
Canada
Prior art keywords
predetermined
electrodes
voltage level
output
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002261703A
Other languages
French (fr)
Inventor
Gunter A. Hofmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetronics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2261703A1 publication Critical patent/CA2261703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • HELECTRICITY
    • H03ELECTRONIC CIRCUITRY
    • H03KPULSE TECHNIQUE
    • H03K3/00Circuits for generating electric pulses; Monostable, bistable or multistable circuits
    • H03K3/02Generators characterised by the type of circuit or by the means used for producing pulses
    • H03K3/53Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback
    • H03K3/57Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback the switching device being a semiconductor device
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/02Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

An electroporation method and apparatus generating and applying an electric field according to a user-specified pulsing scheme. Advantageously, one such pulse includes a low voltage pulse of a first duration, immediately followed by a high voltage of a second duration, immediately followed by a low voltage of a third duration. The low voltage electroporation field accumulates molecules at the surface of a cell, the appropriately high voltage field creates an opening in the cell, and the final low voltage field moves the molecule into the cell. The molecules may be DNA, portions of DNA, chemical agents, the receiving cells may be eggs, platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria, fungi, yeast, sperm, or other suitable cells. The molecules are placed in close proximity to the cells, either in the interstitial space in tissue surrounding the cells or in a fluid medium containing the cells.

Description

ELECI'ROPORATION El~LOYING USER-CONFIGURED PULSES

TECHNICAL FIELD
The present invention generally relates to electro-cell manipulation. More particularly, the invention concerns an electroporation apparatus and method forgenerating and applying an electric field according to a user-selected pulsing scheme to more efficiently introduce molecules into cells and minimi7~ damage to cellular tissue.

BACKGROUND ART
A cell has a natural resistance to the passage of molecules through its membranes into the cell cytoplasm. Scientists in the 1970s first discovered "electroporation", where electrical ~lelds are used to create pores in cells without causing permanent damage to them. Electroporation was further developed to aid in the insertion of various molecules into cell cytoplasm by temporarily creating pores in the cells through which themolecules pass into the cell.
Electroporation has been used to implant materials into many different types of cells. Such cells, for example, include eg~s, platelets, human cells, red blood cells, mammalian cells, plant protoplasts, plant pollen, liposomes, bacteria. fungi, yeast, and sperm. Furthermore, electroporation has been used to implant a variety of different materials, referred to herein as "implant materials", "implant molecules", "implant agents". Namely, these materials have included DNA; genes, and various chemical agents.
Electroporation has been used in both in vitro and in vivo procedures to introduce foreign material into living cells. With in vitro applications, a sample of live cells is first mixed with the implant agent and placed between electrodes such as parallel plates.
Then, the electrodes apply an electrical field to the cell/implant mixture. Examples of systems that perform in vitro electroporation include the Electro Cell Manipulator ECM
~ 25 600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc.

W O 98/lOSlS PCT~US97/01088 With in vivo applications of electroporation, electrodes are provided in a caliper that grips the epidermis overlying a region of cells to be treated. Alternatively, needle-shaped electrodes may be inserted into the patient, to access more deeply located cells.
In either case, after the implant agent is injected into the treatment region, the electrodes apply an electrical field to the region. Examples of systems that perform in vivo electroporation include the Electro Cell Manipulator ECM 600 product, and the Electro Square Porator T820, both made by the BTX Division of Genetronics, Inc.
One type of in vivo electroporation application under research is electrochemotherapy, which uses electroporation as to deliver chemotherapeutic agents directly into tumor cells. This treatment is carried out by infusing an anticancer drug directly into the tumor and applying an electric field to the tumor between a pair of electrodes. The molecules of the drug are suspended in the interstitial fluid between and in and around the tumor cells. By electroporating the tumor cells, molecules of the drug adjacent many of the cells are f~rced or drawn into the cell, subsequently killing the cancerous tumor cell.
Electroporation in this application is especially beneficial because electroporation can help minimi~ the amount of implant agent used, these chemicals frequently being harmful to normal cells. ln particular, less of the implant agent can be introduced into the tumorous area because the electroporation will enable more of the implant agent to actually enter the cell. Electroporation is also beneficial for chemotherapy because some of the most promising anti-cancer drugs, such as Bleomycin, normally cannot penetrate the membranes of certain cancer cells. However~ recent experiments with electroporation demonstrated that it is possible to insert the Bleomycin directly into the cells.
Known electroporation techniques (both in vitro and in vivo) function by applying a brief high voltage pulse to electrodes positioned around the treatment region. The electric field generated between the electrodes causes the cell membranes to temporarily become porous, whereupon molecules of the implant agent enter the cells. In known electroporation applications, this electric field comprises a single square wave pulse on the order of 1000 V/cm, of about 100 lls duration. Such a pulse may be generated, for W O 98/10515 PCTrUS97/01088 example, in known applications of the Electro Square Porator T820, made by the BTX
Division of Genetronics, Inc.
Although known methods of electroporation may be suitable for certain applications, the electric field may actually damage the electroporated cells in some 5 cases. For example, an excessive electric field may damage the cells by creating permanent pores in the cell walls. In extreme cases, the electric field may completely destroy the cell.
Attempting to ameliorate these undesirable ef'fects, at least one application has proposed the use of multiple pulses. One application, for example, proposed use of an 10 electromechanical relay to provide consecutive first and second pulses. S.I. Sukharev et al., Biophys. J. Vol. 63, November 1992, pp. 1320-1327. More particularly, Sukharev uses an electric field pulse 100 as shown in Figure 1. The pulse 100 includes (1) a first, narrow duration, high voltage pulse 102, (2) a delay 103 of ~t, during which no pulse is generated, then (3) a second, wide duration, low voltage pulse 104. The first pulse 102 was intended to porate the membrane, whereas the second pulse 104 was intended to electrophorese DNA into the cell cytosol. Sukharev tecoL~nized that the delay 1()3 should not be excessive.
Although the Sukharev system may provide satisfactory results in some applications, this system may not be completely adequate f'or certain other applications.
20 Some users may find, for example, that Sukharev's electroporation does not effectively move enough molecules of the implant agent into the target cells. This results from an excessive delay 103 between Sukharev's first 102 and second 104 pulses, as recognized by the present inventor. The pores of a cell, created by electroporation, stay open for a finite time, largely depending upon the cell's temperature. Thus, the effect of the first 2S pulse may start to significantly decay (thereby closing the cell's pores) during the delay between the first and second pulses. In some applications, this may be sufficient to completely nullify the first pulse's effect upon the cell by the time the second pulse occurs. As a result, the efficacy of Sukharev's electroporation may be insufficient in some cases. Moreover, lacking an effective first pulse, the second pulse of Sukharev's 30 system may need to be increased to the point where it permanently destroys cells.

~:~LENN~IS~YS~08 -4- REPL~CE~lENT PAGE

The dclay d~s~ ed above i6 inherem to the Sukh~rev system due to the use of ele~ll u,"~,I.anical re~ay~. Sukharev uses independcnt pulse generators, whose outputs ~rc selectively coupled lo output clc~Llu~c5 by a rclay. As known in thc art, howcver, the switching of an d~c~l.,"~echuucal rclay typically takes a ~i~nificant amount of time, 5 sorn~tim~s e~en S0-100 m~. Therefore, the efficacy of the implarlt agent achie~cd by Sukharev n~y be too low for somc applic~tions.
U S. patent 4,663,292 cntitled ~'High-Voltage ~iologica~ h~a~ramolecule Fusior.
System " tcaches ~fan elc,.l~opo~ati~n device using ar~ outp-lt high-vol~age tranformer for pulse duration control of ~n output di~charge pulse of spccificd voltage rn~ tn~l e - 1~ PCT application WO 91118103 entitled Method and Device for MaJ~in~ ing Cells Permeable," teaches of an clcckopora~ion dovicc thllt controh dischargc pulsin~ by applyin~ one ~hor~ h electric field pulse to living cells undergoin~ el~ctroporadon to rn~lce thesc ceJI~ p~ .c~blc to molccular ~ent materials to bc in~roduGed to the cell. I~ex~, this devicc ~cnera~cs at Icust onc longer elc~trical pulse dischar~c of a lowcr elcctric field gn~ de Thu~ as recognized by the prcsent inventor~ cxistin~ clcctroporation sy~terns m~y no~ be s~itable for certQin application~ duc to thc ~cneration of an exce~sive electn& ficld or due to the delsy betwoen adjacent plll9CS. Furthcrmorc~ m~ny existing electropor4tion systems laclc s~mci~t control over the par~neters of the electric field pulses such as 20 amplitude duration, number of pul3e~s, etc.
, ;
D~SCLOSL~F. OF ~IVENT~ON
l~roadly~ thc present invention concerns ~n elcctroporation method and apparatusfor 6~ ating and applyir~ an elcctric field ~ccordit~g to a user-specified pulsing schcme.
One eY~ of such a pulsing schane il-rllld~C ~ low voltage pulse of a first duration, 25 ir~me~ roly followed by 8 high voltage of a ~ccont dur~tion, i.,.l"cl;~tely followed by l~w vol~a~e of a third duration. The invention providcs thc low volt~6c electropora~ion field to ~ccum,Jl~te ~nolec~ at tho surf~cc of a ccll, the appropriately high volta~e field t~ croate arl openin~ in the coll, ~nd the final low volta~e fleld tO move the n~leeul~ in~o the eeU.

nr.~ Sf ~EET

- CA 0226i703 1999-01-27 F ~CI~N~l ~. Pag -5- REPI~CEMENT PAGE

The molcatles may be ~cncs or drugs ~uch ~8 DNA~ p~rtions of DN~, chemical a~ent~ or any otha mnlec~ . The r~olecules arc placod in close proxirnity to the cclls, either in the interstitial tissue surrounding thc cells or in a tluid rTleclium containin~ thc cells.
5~ceordingly, onc aspect of thc prcscnt invention concerns a mcthQd of ~cncrating and applyin~ an clectric fielt according to a user-s~'e~ pulsing schcmc to more efficiently introduce rnolecule~ into cell~ and ~hlh~ze damage t~ cellular tiDsue.
A different aspect of the invention conccrns an a~ar~tus comprising an electrical pulse ~norator to ~nerate ~nd apply such a pulsjng scheme. One crnhodim~n~ of sllch an 10apparatUs utilizes the following co.,.pol,e.,~s. First and second power surpliçs provide first and sccond rcJ~ec~ e output voltages A transtormer, with prima~y and secondaly windin~s, ha~ a pair of output te~.~.in&ls cc)uplet to the secon~ y windjngs. A first switch, rcsponsive to ~ first ~atin8 signal, applies thc first output voltage to the primary windin~.
A second switcl; responsivc to a second gatin~ si~nal, applies the ~econd volts~e directly 1~to thc output terminals. ~ controller, ~cc; ~es uscr ~rerifi~ti~ln cf an output pul~c pattcrn, and pro~ides the tlrst and ~econd ~atin~ 6igna~1s to generate the ~l~erified output pulse p~ttcrn at the output terminal~
The prcsent invcntion provides a number of distinct bene~ts. Generally, thc invention is usoful to introduce ~nol~Gllles of an in~plant a~ent into cells with ~ignificantly 20increascd cf~ectiveness~ The treatment ~cnt, for examplc, may inclute drugs for tresting ,. .cancer, karposi's sarconta~ and a num~er of other ~e~seq and condition~.
ln contrast to prior ~ ngcn.enls u~ng a const~nt IcveJ clectr;ic fieJd, the stcpped pul~c of thc inveJ~tion minimizes ccll darn~ge by using a low volta~o dectric ~ield before and aRer cell pcre~ ue createt. The inve~tion thus l ~lilLl~U~s th¢ exposure of cclls tc hi~h 25volt~ge eJectrica~l ficld~, rcducing possible damage to the cclls. Moreover, the 3tepped pulsc of thc invcn~i~n aJso saves cnerW, sincc the ~irst and third pulses usc Icss voltage than prior ~rrangements.
~n attition, by ~sin~ elccl. o~or~L,on to open cell~ for receipt of nlrle lJle~ of an implant agent, the invention i~cre&~s the efficacy of the a~ent. Consequcnt~y, Icss of the 30implant agent i5 n~eded, thcrcby rcducing any ~idc c~rccls of thc implant agent.

A.~l~?ln~3 sHEET

-- , ~ .. . . . . . . .

oa~ 5W ~rPo~
-6- RE:PL~ PAGE

Another benefit of the invcntion i5 that, regardless of how long voltage is applied to ~he trar,;,l~, .,.~,'~ prima~y winding, resultant tran~f~rmer saturation limits the duration of the co. . e~pon~ g O~ltpUt ~ignal c~n thc transformer's secondary windin~. Thi3 prevents dama~ge to the treated cells, whi-;h mi~ht otherwise resull from prolon,ged applic~ion of 5 volta~c to ~he transformer's primary winding. Another atv~ta~,e of the invencion is that the tra~sformcr's output is floatinR, and therefore no ~ubst~nti~l current will flow if the patient i~ c~nnccted to snother carth or ground polentia].
The invention also pro~ides a number of othcr b~ncfi~c, as di scl~sed in greater detail below.

.. ..
BR~FF D~.C~ TlON OF DRAWTNG
Thc objects, ad~an~a~es and feature~ of this invcntion uill be rnore readily appreciated ~om thc following detailed de~cription, when rcad in conjunction with the accompanyin6 drawin~, in which:
FIG I is a di~~rarn illustratin~ an electroporation wan~eform in accordancc with the ~s pri~r art;
~G. 2 i~ a dia~ra~n of the hardw~rc components ~nd im~reoJmec~ions of a pul~c generator pursuant to one aspect of the present invention;
FIG. 3 is a di~ram of ~n e~cemplaly ar~iclc of m~ f~c~l~re~ comprising a datA
storage medium, in ~ccord~ncc with one aspect of the present invention;
FlG. 4 is a flowch3r~ illustr~ting an exemplary sequcncc of method steps in -.. ;.
accord~ncc with nne aspect of the prescnt invcntion;
FlGS. S-9 arc dre in~s of ilh~strative elc~troporation pulsing schemc~, pursuant to thc invenlion; asld FlG. 10 is- 8 flowchart illustr~tin~ an .-Yon~r~ equence of method steps in ''5 accordsnco with one cxample of thc prescnt invention.

N~ED SHEET

t~N
-7- REP~CEMENT P~GE

BEST MODE FOR CARRYING OUT T~E lNV~~1TrON

~ARDWARE COMPONENTS ~ lNTERCONNECTlONS
As mentioned abo\re, one aspect of thc present invention concerns an improved electrical pu~se ~c~ tor capable ot'generating and ~pplyin~ ~n elcctric field ~ccording to 5 a user-sekrted pulsing scheme ta more efficicntly introduce moiecules into cells and mininnize dama~e to cellular tissue. Fi~ure 2 depicts an excmplary pulse generator 200 The gcnera~or 200 inrl~des a number of diffierent corrlpon~r~t~, described ~ follows.

- Power S~IY
A power supply 202 providcs a rcl~ble source of desired v~llagc !evels ~r use bythe generalor 200. The p~wa supply 202 reccives an input voltayc~ such as 11 OV or 220 VAC from a power source 203. ~ dividcr 204 convert~ the input vcltage into rnultirle refore~cc voltages ln the illu6trated embodl-.~cr.l. r~ voltzgcs of 500 ~t (~. C ~ reside on thc divider ou~put lines 204a-204b.
Thesc voltages are provided to c~ ctors 2û6b-2û7h of first and second re~pective~5 transistors 2~6-207. Thc tr~nsistors 706-207 arc selectively gated to apply thcir input voltages to stop voltage nodes 208.209. The selective ~ting ofthe transistors 206-207 is performed by re~pcctive cornparators ~ 213~ whlch tri~ger gA~es 206a-207a of thetransistors 20~-207 when voltages at ;he s~ep voltagc nodes 708-209 dips below volta~es est~hl;r~ d on 3tep voltage inp.n line~ ~16-21 î For example, when the c~ pQlalor 2l2 20 detcrn~ines th~t the voltage on the step voltage nodc 208 is less than the voltage on the prc-set input line 216, the comp~rator 212 activ~te~ the ~ate 206a of the transistor 206, c~using the transistor 206 to couple tlne input volt~ge of the divider 204 directly to the 5tep voltage node 208. Thus, thc transifi~ors 206 maintain substantially con~t~n~ volta~es at the respecli~e step volta~o nodc~ 208-209 in accordance ~r;ith thc stcp voltagc input lines 21~-A,~~NL~!,-3 K~Y.'~O~ IflX "~j CA 02261703 1999-01-27 - --8- REPL~CII MENT P~GE

Ençr~v Re~eryoir~
Thc ~cncrator 200 also inrl-~d~ cllcr~y reselvoirs 220-2~1 coupled to respectivestep voi~a~e nodes 208-209 E~empl~y cnerW rcscrvoirs 220-221 may comprise cap~cit~r3, ~uch as 3200 ,uF, S00 V electrolytic capacitors These capacitors arc aFpropriate for r~m~lm otcp voltagcs 2~8-20~ of 500 ~/ (D.C,).

Tran~for~er Thc generator 200 also in~ludes a transfonn~r 224, which include~ a primary windin~ ~24a and a second~ry w~nding 224b Thc t,~r~fo.,..e~ 224 p;ef~)y demon~trates - - Iow leal~e induc~nce to advanta~eously provide A fast pulse rise time, on the order of se-eral micro~econds. Prefcrably, thc transformer 224 exhibits low inductancc, on the ord~r of several ,IH Thc~c featurcs rn&y bc provided by winding the ~r~nsr~ n.er ~4 w~th a single cable of twelve separate, twisted conductors of which six are c~nn~ctetl in parallel for the primary, six are connected in series fcr the 9ecol~Ao~y. This provide~ a 1 6 ste~up ratio In addition, A separate low volta~c D C bias winding around the core may be used I S to employ d~e fi~ll flux sw~ng of the tran~o~ ,c. 's core. A3 an example, the transformer may utilize a core ~n4de of laminated iron.
Thc ~ ,.cr 224 may advant~e~)ucly be constructed ~o ~a~urate if the pu1sc Iength exceeds a maximum prcscr~bed value~ thereby protccting a patient fron~ excesiive electrical ener~y Pl cfc~bly, the trar~formcr ~24 is capab~e of carrying ~ 3 V-scc (3000 V x 100 ~L~C) before saturation, Anothcr ~ aMBge ofthe transformer 2~4 is that its output is floatin~, and no sub3t~ntial currcnt will flow if the patient is connected to anothcr earth or ground potential.
The second~y wlnting 2Z4b is coup~ to outpus nodcs 230-231, which ~re emboticd by clcc~rode~ in the illustrated application. The electrodes (not shown) may comprisc para~lel plate electrodcs, necdLe clcetr~des, caliper clc~,lrodes, or ancther arran~ement of electrotes Furthcr discudsion of ca~iper elec~lûdcs ~ppcars in (1) U.S
r'atcnt Application No. Q8f 5 37,265, cntitlcd "Mcthod of Troatment U~in~ Elc.,~rupc~l~tit~n l~lediatcd Delivery of Dru~s ant G~nos", filed on Sc,~ . 29, 1~9S, and (2) ~ev et ~1., "Elec~rochemoshorapy- a novel mcthod of canccr ~r~ nt~ll Cancer T~ ..c.,l Rcview~
(l994) 20, 1 OS- I I S A usefill example of neetlc Iccll~des is di~G~ ed in U.S, Plltent Al~/J~N~ED S~EET

~ - CA 02261703 1999-01-27 -g- Rli:PLACEMENT PAGE

5,702,359, entitled "Nocdle Eloctrndos For Electroporation Mediated l~elivcry Of Drugs and Gcnes "
The load b~ween the electr~des 230-231 is represented by a resistor 234. In the illustrated c,~bodi.~ent, thc load 234 comprises a number of cells, ~hich may be in v~
or in vivn ~amp!es of eggs, plate~e~s, human cell3, red blcod cells, mammalian cells, plcnt pro~npl~etq, plant polle~l, liposnmes, b~cteri~ .3i, y~st, sperm, or othcr colls.
To protect th~ energy reselvoir ~20 and power ~upply 202, a diode 236 may be placcd between the energy rcscrvoi. 220 and thc electrodc 23~. Likewise, to protect the cncrgy rcser~oir 221 and powcr ~uppiy 220, a diode 237 may be placct betwcen t~he seco~ Rry winding 2~40 and the olcctrodc Z30.

Switches The ~enaator 200 al90 include~ switcbes 22~-227 to selectively enabie current t~flow through thc primuy and second~r~ winding~ 224a-224b, r~Qp~c~ ely. In one exempla~ Gonstruction, each switch 226-~27 may comprise an insulatcd ~ate bipolar ~ransistor ("lGBT"). such as a Fuji Electric brand 1MB1400F-060 model IGBT.
The switch ~6 and ~he ener~y rescrvoir 221 3re cnlJpled in serics, this ~eries combination bein~ att~ched ir. parsIlel wi~h thc primaly winding 224a. When vo!tage is applied 10 a ~,3te 226a of the swi;ch 2~6, thc collectDrs 226b and cmitter 226c are clectncally con d. Thus, Ihc encr~y reservoir 221 is cfl~:ctively placed in parallel with the prim~ry windin~ 224~. This pt,'rTnit3 currcnt from the enerW reservoir 121 to flow through the primary winding 224a.
Simila~ly~ the sw~teh ~Z7 and cnergy reservoir 220 aro coupled in senes, this scries c~mbinatior. bcing auachcd in puallel wilh the sccc~n~ - ry winding 224b. When voltage is ~pplied to ~ Bat~-227a of the swi~ch 227, thc collectors 227b and emittor 227c are electr~cal'y connected. Thus, the cnergy rescrvoir 220 is cfleclively placed in puallcl with ~he secc~ndary windin~ 224b. Tnis pamits currcnt from the cnergy rescrvoir 220 to flow throu~h the loHd 234.
Advant~geousl~, none nf thc ener~y re~e~Qirs 220-221 or ~witches 226-227 ~rounds ~e winding~ 2~ 224b. Th~ windings 22~a-224b arc thacfore clectric~

~~NGCD S~EET

.. . ..

~ CA 02261io3 i999-01-27 I~:U'I ~I!Yl~ TJ~
.

.10 Rl~rLAl~ MENT PAGE

floating. As a result, no ~ubqt~nti~l curTcnt will flow throu~h a patient or other load 234 that is coMectcd to at~other earth or ~round pot~

Controllcr ~nothcr componcnt of the 3enerator 200 i~ thc controller 240, which mana~es S operation ~f thc switchcs 22~-227. Broadly, the controller 240 re~ te~ the on-times and off-times ofthc switches 226-227 in accordancc 8spcrifi~d schedule, thercby ~enerating a prcdctcrmined pulsing scheme at the electrodcs 230-231. When the controller 240 trig~er~ tho switch 227, the volta8e of the onergy rcscrvoir 220 is applied ta the eJectrodos 230-231. When the wntroller 240 triggers the switch 226, thc voltage of the energy rcser~oir Z20 is applied t~ the transformor 224, where it i~ multiplied by six and applied to the elcctJodes 23 0-~3 1 . The contrclla 220 ma~ also trigger both svvltchos 226-~27 to apply anadditivevolta~e,comprisingthcsumofthestepvol~agcs208-209,totheelectrodes230-2~1 .
The controller 240 rnRy comprise a computer, di~ital or anal~g proces~in~
apparat~, pro~rammable logic array, hard-wircd logic circuit, application specific intcgratet circuit ("ASIC"), or anothcr suitsble device. ln an excmplary embodiment, the control~cr 240 may comprisc a PIL 16C64 M;crochip microprocessor accomp~nied by appropriatc RAM and ROM modules, as desired.
Prcfcrably, the controllcr 240 is coupled to a u~cr interfacc 242 for ~Ych~ngine d~ta , 20 with a uscr. In the illustratcd examp~e, ihe u~er may nperate the user interface 242 to input a desired pul~ing pattern eO bc applicd t~ the elcctrotcs 2~0-'~31.
As an cxample, thc u~cr interf~ce 242 may includc ~n ~Irl~numenc Iccypad, touch screen, computer mouse, push-buttons ~nt/or togglc switchcs, or another suitablccomponent to rccoivc inpu~ ~om a human user. The user interface ''42 may al90 includc a CRT scrcen, LED s~reen, I CD screen, liquid crystal display, printer, displ~y pancl, audio speaker, or ~nother suitable CO~ JOnCllttO convey data to a hurnan user.

Preferable n~U~n P7~neters Tho cloctricsl requiremcnt~ can be deri~ed from the ficld strength, which wa~
dcte "~ ~1 efflcac~ous flrom in vitro e~c,~",~ w~th tumor cells and dru~, typiullly 1200 fND~D S,lEET

L .. ~ ~, ., v ~ i CA 0 2 2 6 1 7 0 3 1 9 9 9 0 1 - 2 7 P \a ~1~1 ~\~)64~ ~

-J 1- RE:P~ACEM~NT PACl~

- 13û0 V/cn~, Qnd a pul~e Icnyth of about 100 ~9CC. The maximun~ VOItBgC ofthc generator derives frons the nlaximum tumor 3i2:C onc w~nt~ to trcat. rn ordcr to treat tumors up to 2 crn diamcter with caliper elcctrodes (parallel plates) at ficld strength of 1~00 ~Jcm, an Qperating voltage of 1300 x 2 - 26~0 V i6 required; thc gcncratDr W~l9 dc~i~ned to ~cncratc 5 3ûD~ V maximum to providc ~omc extrs mar~pn.
Thc tissucJtumor specific resis~ivi~y was aisumed ta be as low as 10û Oh~n x cm.With an clectrodc arca of 3 cm x 3 cm = 9 cma~ the rcsi~tance is ~2 Ohm. thc intcrnal impcd3nce of the generator sbDuld be at least a hctor 10 lowcr than 27 Olun so that no subslantia~ drop in volta~c occurs bctwccn charg~n~ and delivered volta~e. With th~
10~ m voltage of 3000 V and a lo~d impcdance O f 22 Ohm, the switchin~ requi. en~e.,ls ~~ from B partial c~p~ritQr dischar3e to generate a squuc pulsc are a very Ylhs~A~ 4C0 kW.
The dcsired m~y~ m permeation pulse len~h is 100 ,lsec; this re~ults in ~n energy per pulse of 40 J. For the cnllection an~ clc~ phoresis pu!se parameters, a maximum volta~ce of 5(:)d V and m~ximum pulse length ~f 20û mscc may be used.
15The r~s~ m load currcnt is about 136 A. which translatej int~ a primary current of 6 136 - 816 A, which the switch has to carry and turn on and o~ Thc switches 2~6-227 can prefcrably maintain continuous cur.rent 800 A for I msec. The n~Yiml Im volta~e is 600 V. Transicnt spikes are limited to a rn~ m of 5~0 V for a 10% safety mar~in This requirod carcfill low induct~nce l..cc~~ ~ 1 assembly to rc~uce trano;~nt~ and ~ be 20 able to get as c30se as safe~y feasible to the maximum volta~e limit of the lGBT.
The l~ad i.npcd~.cc of 22 Ohm is transformed to the primaly: 2V6x6 - 0.61 Ohm.
- A to~al inten~al impedance of 0.0~5 Olun was achieved on thc primaty side of the transfonncr, which tr~nslates to an equi~alent impe~ rc of 1.98 Ohm ~n the secondary.
Such a low i~ ,cd~.nco ca~ lead to excessi~e curronts in case of ~n arc or short circuit and 2~ these would destroy the expensiv~ ~witchin~ lGBT. The ~GBT can be confi~1red to contain a currem lin~ting feuu~e, which tums the switch offwilhin a few ,u~ec in casc of e~c~s1ive load currcnt~ ~uch a~ might occur in case of an arc ~r a short circuit. By in~hci~g an arc in the secnnd~ NC mcasurcd ~ beniBn shut down ofthe IGBT within S ~lsec, as soon as thc cwrent exceeda ~bout 9ûO A in the primary, co~ .onding to I SO A in the secQr~rl~ry.

A.iA~.;NDED ShEET

J ~ _L~ S' '- - CA 0 2 2 6 1 i O 3 19 9 9 - 0 1 - 2 7 - - - --- -= --12- ~PLACEMENT PAGE

The necess~ry capacitor sizc can bc ecti~ ted from the n ~Yiml~m allowable voltage drop across th~ load of S%. The charge conducted in the prirnary pulse is 100 ,us x 816 A -0 08 Cb. If thj~ :Ihould be 5% ofthe capwitor b~nk, the bcnk needs IO hold 20 ~ 0 08 = 1.6 Cb. ~t 500 V Tnsxirnum, the requircd c~pacity ~s C = Q~V = 1.6/jOO = û.0û32 F or 32~0 5 ,uF. The ener~y ~tored in thesc c~r~citors is 400 Joule.
Fcr the collection and clccllul)horesis pul~e, a second capacitor dischar~c circuit delivers the lon~er puls~ Ico~ths (srvcral 100 mscc~ and low voltage (50~ ~J) without the pulse tran~fonner. The low vnltage circuit and the hi~h voltage circuit are decoupled from esch other by ~t~cks of diodes 237 and 236.
,., I û ~PERAT10N
In addition to the vanous hardware c"lbod;n ,c.~t~ describcd abovo, ~ different aspect of the invention broadly co~c~.,.s ~ method for ~4enerating a user-s~,c~,if~d electric field pulsin~ p~ttern to achieve improv~d elcctroporation.

P~la Stora~e !~edia T~i~ method ~ay be imple~lrntP~ for example, by operating the controller 240 to execute a sequence of machine-readable instructions. Thcse instructions may residc in varioug types of data storaue media. In this re~pcc~, one aspect of the present invention concerns ~n ~rticlc of manufActl~re, con~ .,y a dsta storsge medium tan~ibly cmbodying a program o~ machine-re~d~blc instructions executable ~y a di~ital data proce~sor to 20 pcrf~rm mothod steps to ~eneratc a user-specified electric field pulsing patlern tO achieve i..lpr~vcd elearop~ration This d~ta storage mcdium may co..~rise, for exarnplc, R~M con~ained within thc controller 240. Altema~ively; ~he in~uuctions may be co..~ned in another data storage mcdium, such ~8 a rnagnctic data st~rage diskette 300 (Fi~urc 3). Whether conla;nc~ in thc 2S controller 2~0 or clsewherc, the instmc~ion3 may instud be stored on another type of data stora~e medium ~uch as ~)ASD st~rage (e.g. a convension~l "bard drive" or a RAID a~ray)~
magnetic t~pc, clectronic read-~nlsr ".e.no,~ (c.~. ROM), optical ~tora~e dcvicc (c.~.
WORM), papcr "punch" cnsdc~ or othcr data storage media. In an i~lustrative r mhod~

N~D S~EET

... _ .... , . ~ . ...

LoeN~ p~ pc~

-13- Rli:Pl.ACEME~T PAGE

of thc invcntion~ thc ms~l~inP-re~dable instruction~ m~y comprisc line~ of compiled PIL
16C~4 Microchip m~chinc code Opcrational Steps ~s merltioned above, one aspect of thc ~vention broAdly concerns ~ nlethod for 5 generatin~ a user~spccified electric field p~llsing pattcrn to achicve improved electroporatio~ Figure 4 ~how~ a sequonce of mcthod s~eps 400 to ilJustrate one examplc of this a~pect of lhe prescnt inventi~n. F~lr ea~e of cxp!~tion, but without ~ny limitation intended thaeby, thc sequcnre of Figure 4 is de~ cd in the specific context of the pL;lse - generator 200 descli~cd abovc.
Af'~cr the steps 400 are initisted in t~sk 40Z, the controller 240 in tas~ 404 rcccives user input spec;fi~ing an nutput pul~c pattan of one or more o~ltput pulses. As an cY~mrle!
thi~ uscr input may be recei~ed fiom the uscr intcrface 242. As an alternative, the user input may bc reccived from another electronic dcvice, or even a pre-stored record.
P~fL.~bly~ the uw input specifie~ a duration for each pulse and also specifying either a "high" ~utput volt~gc or a "low" output ~olt~ge. Next, f~r each pulsc of low predeterrnincd voltage, ~he pulsc ~encrator in task 404 geT~erate~ thc "low" predetermined voltagc at the outpu~ terminals 2~ and 231 for the s~ec;~c~ duration. More particularly, the comroller 24~ may gene~ate a l~w voltage pulse by ~ating the s~4itch 227, thercby permitting thc cnergy rese~oir 220 to discl~rgc through the load 234.
,_. 70 ~Igo in task 404, high voltage pul~es ~re gencratcd a~ the second~y winding te~rLinals ~y concu~t~ applyin~ another voltage to thc pnmary winding ternuTlals of thc transt-ormer for the specified dlJration. Mor~ p~rticularly, ~he high voltago pulsc involves gencr3tin~ thc volt~e a~ di~cu~c~ above, while conclJrrently tng~cring thc switch 226 to penT it the oncrgy rescrvoir 221 to discharRc thrau~h thc prima~y wind~ng 224. As tho voltagc of the re~ervoir 221 is ml~3~ ied by the transformcr 224, a high volt~c is crcated at the electrodes 23~-231. This voltage i5 the additive sum of the voltagcs 3tored in tbe energy reservoirs 220-221. .~J~c~ cly, a lesser "high~ voltage OUtpUI ma~ be createt sololy by tri~8ering thc swi~ch 226, without involving thc switch 22~.

AM~.D SHEET

.~

''''S';!_'"'_''"'-'.'"~ ~'~ CA 0226i703 1999-01-27 F:~LE~r~

14 REPLACEMENT PA&E

Onc or morc of the above-rnentiDned pulses are therefore gcnera~ed in task 404 to produce ~he us~r-~pecified pulsc pattern~ er thc u6er-crocified pulsin~ pattern i9 creatcd complcted in task 4041 ;he routine 400 ends in taYI~ 106.

~p:ration ~,Yith rrcf~ ~ PU~ Pattern As ~nc~ti~n~d abc~e, the p~e ~enerator Z00 prnvides ~ uscr-specified pulsc pa~:tern compnsing ~ne nr m~re pulses nf "hi~h" andlor "low~ output voltage. Fi~urcs S-~ illustrat~
v~rious exe~nplary pulse shapcs, which ~y be ~sed alone or in comb~nation to constitute the user-spccificd pul3in~ 3chemc.
-. Although cach of the pulsin~ pattcms of ~i~gures 5-9 may provide distinct adv~ 6es for diffcrent S-rpli~ ons, the folJowing description highlightC the f~atures md opcration ~f a pattern ~00 (Figure 7) to illustratc thc opcra~ion of the invention, both electrically in the pulsc gencrator 200 as well as physiolc)gically in a ceJI sample.
Thc p~ttcm 100 compsiscs ~ "steppcd pattemU, in th~t it provides first, ~econd, and third vol~age ievcls 702-?û4. One, tw~, or all of these volta~cs m~y bc the sarne, if de~ired.
I S The pulses have first, second, and third durations 7û6-?08 ~n thc prc~cnt eY~n rle, the firs~
and third voltagas 706, 708 providc a 500 V (D C.), v.hereas the ~ccor.d volta~e 707 provltes 3000 V ~D.C.) Figure 1~ describcs ar~ illustrative sequcncc 1000 involved in gener~ting and apply~ng the stepp-d pa~tam 700, and thc physiological effiects caused by app' cati~n ofthe pat~ern 700. A.~r th~ sc~uen.e be~n6 in task 1002, the user intertace 242 recc~es user input in taok 1004. In thc illustraled embodimcnt, thc user input includcs thc user's specificuion of a desircd clcctrnporation pul~inR patt~rn, including a duration ~d volta~e ~evel f~r each portion of the pattern.
In an ~Iternative rn~odiment thc user m~y speci~ a desired ~rq~ih~e of electric field to bc appiicd by thc tra~sformer 224, and a me~surement of tho 8ap between the electrodes 230-2~1. In thi~ case, the controller 240 rnay compute the appropnate voltagc for the transformer 2~4 to gen~ratc in order to ~?Piy the desired electric fidd, for example by nrJXiplying thc elcctrie ficld by the ~ap. In ~ne e~nb~diment~ the ~ap measurcm~nt may be input by the uscr manually. Alternatively, thc 8~P may be mechanically measured and A~JD~D SHEEt ........ . . . . .

~ CA 02261703 1999-01-27 F '''~ g EPLACEI~ENr PAGE

electronically fed to the controller 24~ by automatcd means such a~ ~hown in U.S. Patent No. S~439~440.
Concurrently with task 1~04, the power supply ZO~ ~cn~- ~lcs the reference voltages at the output n~des ~8-209. In thc prc~ent cxamp~c, the rcfer~nce volta~e~ 208-20~ of S00 S V (D.C.) uc used. Gcncration of thc re~èrence voltages in task 1008 char~es ~hc energy reservoirs in task 100~
A~or task 1008, ~n oper~tor in ~ask 1010 ~pplies molcculcs of an implant agcM toa treatment sitc. Thc implant a~ent m~y comprisc one or more types of DNA, genes, andlor vanous chemical ~Cnt9. ln the case of elcctroch~ th~raphy, one b~fi-~l implant ~ent i9 Bleomycin.
With a livc patient, the trea~ncnt site coll.pl;9e9 a region of livc CC~3, and the operator is pr~faably a nurse or physician who applies a liquid implant ~gent by il~iec~ g i~ with a hypodcnnic noodle.
In the case of in vitro ap~licP~ion of the implant a~ent, however, the trea~n~ s~te 1~ may c~ ti~lte a cell samplo placcd in an approp..ale containe~. In this cxample, the opaation may be ~ laboratory tce~nici~n ths~ applies a liquld implimt agerlt by pourin~, eye-dropping, or other~vise introdurin~ thc a~ent into Ihe cell sample.
Step 1010, whether performcd in v~w or in vitro, places thc implant a~cnt b~,lwecn the in~c~ticcs ofthc cc118 at thc tre~tn~t site. ~ext, in task 1012 the operator ~lpplies ~0 electrodcs to thc ~rwt~.,e..~ site. In the case of a live patient, this m~y involve ~ripping region of cells through thc dcrmi~ with a c~ljper, inscrtin~ 9 nccdlc ~rray i~to the patient'3 ~~ tissue, or anothcr ,croccd~re. With an in vitro t~e~ lwl~ sitc, task 1012 may i~vol~e placing the cell samplc bdwccn a pur of plate-shaped electrode~ provided for that purpose~. A~
an ~. d...jl~, p~ue shaped clc~.~rodcs may be used, such a~ thc BTX ~rand cuvettes, part 25 numbcr ~40. ~ -A~ter t~ lû 12, thc co.,tr~ 24û in task 1014 8ates the switch 227, dischsrgingthc ener~y rêscrvoir 220 ant thercby applying the rlow" volta~e to the electrodes 230-231.
Tbis step ~c~m~llat~ r ~ 9 of the impl~nt s~ent r~ulr the n)c..ll)rancs of thc cells i~
the cdl ~~nple. ~ di~cG.~.cd by the pre~cnt mvcntors, thi9 StCp m~y bc ~dequately 30 pe.~,n.cd with a rcduced voltage. Acccrtin~ly, the "low" vol~age ofthe cnergy re~crvoir A~DED SHET

.. . . . . . .. . .

F:~l~n~Dl~r~

-l 6- REPLACEI~1ENT PA~E

220 acl,ie~ this purposc, whilc still avoidin~ dam~c to the cells in the sample and saving elc_~lical encrgy.
Figuro 7 illustratcs tssk 1~14 as thc volta~,c pulse tO2. A~ shown, this puJse prefcrably ccmpn~cs a squ~rc wa~e having a dur~tion ~6 of about 1~ 20~ nuec Md ~5 vol~age of abaut S00 V (D C ). D~pPn~ing upon the ap~lic~ n~ however, Jill~,.,.n paramelcr~ may be sub~ti~u~ed to define the pulse 702.
A~er task ]û14, thc controller ~40 in ta~k ~016 gatcs the ~witch 2~6 ~while cont~nuing to gatc the switch 227). This create~ a "hi~h" voltagc upon thc clcctrode~ 230-231, cG.~ponding to the sum of the ~cf~ uce voltages 208-209. This hi~h volt~e is 10 suffit,ienr to s~fely create small pores in the cells af thc tissue sample. This inventors '~ believe this d~ect ~o result ~rom electroph~fw;s, the actiDn of Coloumb fDrces ~n the chargcd ~olecules of the implant agcnt.
Fig~Iro 7 illustratcs this ~tep as the volta~rc pulse 703. As illwtrated, this pulse p~c~. ably comprises a sg~are w~ve h~vi ng a duration 7~1 of ~bout 100 ~9ccand an clectric 15 fidd n~ dc of ~bau~ 1"00 Vlcm. ~!epen~ing upon the ~ppl ration~ howevcr, ~ c.ent parameter~ may be substituted to definc thc pulsc ?02.
Advant~o!~oly, thc pulsc generator ~00 au~mntica1ly limits damage to c~lls ofthetissue sample d~lring this stcp. In particular, when thc volta~c ~om th~ pr~nary winding ~24a ~ tcsîhesecon~rywindin~224b, thevalsa~eprcscntedbythc~econtarywinding ~0 224b ~cg~ns to decay, in ~ccord~nce with known principles of tl a,.sro, ..,~ operaticn. Thu~, _ eYen if the volta~c applicd to thc primary winding 224a i~ ~pplied fDr an cxces~ve length of time, the 3ac~,)Jn,y wlntin~ 224b 8'JtomatiC8J]ylimit9 ~he ~issue samplc's exposure to t~S ~ ~ v21tage pulse.
Ncxt, in taslc 1018 the c~ntrollor 240 ce~scs ~ting of thc swi~ch 226 w~le 2~ cor~tinuing to ~atc tho switch 227. This step pern~ts thc mol~cul~ o~the impJant agent tc transit thc ccll~' pc. ~ le ~uc~ rdnc~l and entcr the cells' cytoplasm.
Fi~urc 7 illustr~tes this step a~ thc volta~c pulse J04. As illu~tr~ted, thi~ pulse pref~rably compAses a squ~re wElve hav~ng a duration 708 of about 1-200 mscc snd a voJtagc of abaut 500 V (D.C.). Dopentin~ upon thc ~pplirqtion, howcver. difEerent 30 parameler~ may be ~ubstinlt~d to define the pulse 704.

~ YO--~

CA 0 2 2 6 1 7 b3 1 9 9 9 - 0 1 - 2 7 F ~a~\D6~r.rr~

REPl.ACEMENT PA~E

Afhr task 1018, the controller 240 relea~es gatin~ of the switch 227, ending thepulsc 700. The4 thc operalor removes the elec~rodcs from the cell sarnple in ta~ 2~, and the sequ~ce 10~0 ends in task 102~.

TTIE EMBODl~ENTS
While there havc bcen shown what are presently conc;~lered to be preferred embodi.~ents of the invention, it will be a~ t to those skilled in thc ut that various ch~nge~ uld modifications carl be m~de herein without deputing from the 9eOpe of thc inventioQ as dcfirled by the ap~...dcd cl~ims , ,. -- - .

Allh~ L{~

Claims (33)

1. In an electroporation apparatus for generating a specified electroporation pulse shape that includes a power source, a transformer, a controller and output terminals configured for connecting to electrodes, an improvement comprising:
a first power supply (209, 221) to provide a first output voltage;
a second power supply (208, 220) to provide a second output voltage, wherein thefirst (209, 221) and second (208, 220) power supplies are separate sources of electrical energy;
a transformer (224) having electromagnetically coupled primary (224a) and secondary (224b) windings, the secondary winding (224b) being interposed between a pair of output terminals (230, 231);
a first switch (227) coupled to the first power supply (209, 221) and the primary winding (224a) and being responsive to a first gating signal to apply the first output voltage from the first power supply (209, 221) to the primary winding (224a);
a second switch (226) coupled to the second power supply (208, 220) and the secondary winding (224b) and responsive to a second gating signal to apply the second output voltage from the second power supply to the secondary winding (224b); andthe controller (240) to receive user specification of an output pulse shape and provide the first and second gating signals to generate the specified output pulse shape at the output terminals (230, 231).
2. The apparatus of claim 1, wherein:
the first power supply provides the first output voltage having a magnitude proportional to a first supply signal;
the second power supply provides the second output voltage having a magnitude proportional to a second supply signal; and the controller provides the first and second supply signals to generate the specified output pulse shape at the output terminals.
3. The apparatus of claim 1, each of the first and second power supplies are electrical power sources that are selectively coupled to and energy storage reservoir and to the first and second switches.
4. The apparatus of claim 3, each energy storage reservoir comprising a capacitor.
5. The apparatus of claim 3, the first and second switch comprising a transistor.
6. The apparatus of claim 3, the first and second switch comprising an insulated gate bipolar junction transistor.
7. The apparatus of claim 1, the transformer having a leakage inductance of less than 10 µHenry.
8. The apparatus of claim 1, the controller including a microprocessor.
9. The apparatus of claim 1, further comprising a user interface coupled to the controller.
10. The apparatus of claim 1, further comprising a pair of electrodes that are each electrically connected to a different one of the output terminal.
11. The apparatus of claim 1, further comprising a diode electrically interposed between one of the output terminals and the secondary winding.
12. The apparatus of claim 1, the second switch and second power supply being coupled in series, the series coupling being electrically attached in parallel with the secondary winding.
13. The apparatus of claim 12, further comprising a diode coupled in series with the second switch and second power supply.
14. The apparatus of claim 1, the first switch and first power supply being coupled in series, the series coupling being electrically attached in parallel with the primary winding.
15. The apparatus of claim 10, wherein the electrodes comprising plate electrodes.
16. The apparatus of claim 10, wherein the electrodes comprising needle electrodes.
17. The apparatus of claim 10, further comprising:
a gap sensor to sense a distance between the electrodes and provide a representative electronic gap distance output signal.
18. The apparatus of claim 1, wherein the controller includes programmed instructions to generate an electroporation pulse pattern by performing steps comprising:
receiving the user specification of an output pulse shape of one or more output pulses, the user specification includes a duration for each pulse and also specifying either a first predetermined output voltage level or a second predetermined output voltage level;
for each pulse of the second predetermined output voltage level, applying a gating signal to one of the switches for the specified duration; and for each pulse of first predetermined output voltage level, applying a gating signal to the first switch while concurrently applying a gating signal to the second switch for the specified duration.
19. The apparatus of claim 1, wherein the controller includes means for electrically coupling the first and second power supplies, and programmed to perform method steps comprising :
(a) to generate a first voltage at the secondary winding terminals by applyinga first voltage to the secondary winding terminals of the transformer;

(b) a predetermined delay after initiating step (a), to maintain application of the first voltage at the secondary winding terminals while concurrently applying a second voltage to the primary winding terminals; and (c) a predetermined delay after initiating step (b), to cease application of the second voltage to the primary winding terminals while maintaining application of the first voltage at the secondary winding terminals for a predetermined duration.
20. The apparatus of claim 19, the controller further being programmed to perform, prior to step (a) from the user specification, method steps comprising:receiving an input specifying a desired electric field;
receiving an input specifying an electrode gap distance; and calculating the first voltage to provide the specified electric field across thespecified electrode gap distance.
21. The apparatus of claim 19, further comprising:
a pair of electrodes electrically connected to the output terminals of the transformer;
a gap sensor to sense an electrode gap distance between the electrodes and provide a representative electrode gap distance output signal;
wherein the controller is further programmed to perform steps comprising:
receiving an input of a desired electric field;
receiving the electrode gap distance output signal; and computing the first voltage to provide the input desired electric field across the electrodes.
22. The apparatus of claim 18, wherein the programmed instructions to generate an electroporation pulse pattern to performing the steps is contained in a portable tangible data storage medium executable by the controller.
23. In an electroporation method for generating an electroporation pulse pattern using an electroporation apparatus that includes a power source, a controller, a transformer having a primary winding that electromagnetically couples to a secondary winding, and electrodes, an improvement comprising:
receiving user input (1004) specifying an output pulse pattern of one or more output pulses, the user input (1004) specifying a duration for each pulse and also specifying either a first predetermined output voltage level (702) or a second predetermined output voltage level (703);
for each pulse of the second predetermined output voltage level (703), applying a first predetermined voltage (702) to the secondary winding terminals (224b) of the transformer (224) for the specified duration; and for each pulse of the second predetermined output voltage level (703), applying the first predetermined voltage level (702) to the secondary winding terminals (224b) of the transformer (224) while concurrently applying a second predetermined voltage level (703) to the primary winding terminals (224a) of the transformer (224) for the specified duration (707).
24. The method of claim 23, further comprising steps before the applying steps of:
arranging the electrodes about a treatment site, the electrodes being coupled across the secondary winding terminals;
delivering molecules of a predetermined implant agent to the treatment site, andafter the applying steps, removing the electrodes from the treatment site.
25. The method of claim 23, the treatment site comprising a region of tissue within a living being.
26. The method of claim 23, the treatment site comprising cells removed from a living being.
27. The method of claim 23, the user input further including at least one of the first and second predetermined voltage levels.
28. The method of 23 wherein the method includes:
(a) applying an electric field at the first predetermined voltage level to a region of cells for a first predetermined duration;
(b) increasing the electric field to the second predetermined voltage level greater than the first predetermined voltage level;
(c) reducing the electric field to a third predetermined voltage level less than the second predetermined voltage level.
29. The method of claim 23 wherein the method further comprising the steps of:
(a) positioning the electrodes relative to a region of cells and delivering a predetermined implant agent to the region of cells;
(b) moving molecules of the implant agent toward the cells by applying a voltage of the first predetermined voltage level to the electrodes for the specified duration;
(c) creating pores in a plurality of the cells by applying the second predetermined voltage level greater than the first predetermined voltage level to the electrodes for a second predetermined time; and (d) moving molecules of the implant agent into a plurality of the pores by applying a third predetermined voltage level less than the second predetermined voltage level.
30. The method of claim 29, the second predetermined voltage level is applied to provide a resultant electric field at the electrodes in the range of 300-3000 V/cm.
31. The method of claim 30, further comprising the steps of computing the second predetermined voltage level by multiplying a desired electric field by measurement of a gap existing between the electrodes.
32. The method of claim 28, the first and third predetermined voltage levels being minimized to minimize damage to the cells due to thermal beating.
33. The method of claim 23, wherein the user input specification to generate anelectroporation pulse pattern to performing the steps is read from a portable tangible data storage medium executable by the controller.
CA002261703A 1996-09-09 1997-01-27 Electroporation employing user-configured pulses Abandoned CA2261703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/709,615 US5869326A (en) 1996-09-09 1996-09-09 Electroporation employing user-configured pulsing scheme
US08/709,615 1996-09-09
PCT/US1997/001088 WO1998010515A1 (en) 1996-09-09 1997-01-27 Electroporation employing user-configured pulses

Publications (1)

Publication Number Publication Date
CA2261703A1 true CA2261703A1 (en) 1998-03-12

Family

ID=24850605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261703A Abandoned CA2261703A1 (en) 1996-09-09 1997-01-27 Electroporation employing user-configured pulses

Country Status (9)

Country Link
US (2) US5869326A (en)
EP (1) EP0925647B1 (en)
JP (1) JP3963955B2 (en)
KR (1) KR100420731B1 (en)
AT (1) ATE216155T1 (en)
CA (1) CA2261703A1 (en)
DE (1) DE69711893T2 (en)
ES (1) ES2175343T3 (en)
WO (1) WO1998010515A1 (en)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636166A (en) * 1995-12-05 1997-06-03 Micron Quantum Devices, Inc. Apparatus for externally timing high voltage cycles of non-volatile memory system
US5914613A (en) * 1996-08-08 1999-06-22 Cascade Microtech, Inc. Membrane probing system with local contact scrub
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6778853B1 (en) 1997-12-17 2004-08-17 University Of South Florida Electroporation device
US6135990A (en) * 1997-12-17 2000-10-24 University Of South Florida Electroporation device and method
AU4219399A (en) * 1998-06-08 1999-12-30 Valentis, Inc. Formulations for electroporation
EP1100576B1 (en) * 1998-06-26 2007-08-15 Genetronics, Inc. Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
CA2337129A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6256882B1 (en) * 1998-07-14 2001-07-10 Cascade Microtech, Inc. Membrane probing system
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6532386B2 (en) 1998-08-31 2003-03-11 Johnson & Johnson Consumer Companies, Inc. Electrotransort device comprising blades
US6150148A (en) * 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6937890B2 (en) * 1998-12-17 2005-08-30 University Of South Florida Nonpenetrating electroporation device
US6314316B1 (en) * 1998-12-17 2001-11-06 University Of South Florida Nonpenetrating electroporation device and method
US7412285B2 (en) * 1999-04-09 2008-08-12 Oncostim, Inc. Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
EP1171195B1 (en) 1999-04-16 2005-03-16 Johnson & Johnson Consumer Companies, Inc. Electrotransport delivery system comprising internal sensors
US6578264B1 (en) * 1999-06-04 2003-06-17 Cascade Microtech, Inc. Method for constructing a membrane probe using a depression
WO2001001949A1 (en) 1999-07-01 2001-01-11 Johnson And Johnson Consumer Companies, Inc. Cleansing compositions
US6762158B2 (en) 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
US7074747B1 (en) * 1999-07-01 2006-07-11 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US20050009717A1 (en) * 1999-07-01 2005-01-13 Lukenbach Elvin R. Foaming make-up removing cleansing compositions
EP1254951B1 (en) * 2000-01-27 2011-01-12 The Mollennium Laboratories Molecule transferring device, auxiliary for molecule transferring device, and molecule transferring method
AU3399801A (en) 2000-02-17 2001-08-27 Yoram Palti Method and apparatus for destroying dividing cells
US8447395B2 (en) * 2000-02-17 2013-05-21 Novocure Ltd Treating bacteria with electric fields
US7136699B2 (en) * 2002-10-02 2006-11-14 Standen, Ltd. Apparatus for destroying dividing cells
US8175698B2 (en) 2000-02-17 2012-05-08 Novocure Ltd. Treating bacteria with electric fields
US7146210B2 (en) * 2000-02-17 2006-12-05 Standen Ltd. Apparatus and method for optimizing tumor treatment efficiency by electric fields
US7089054B2 (en) * 2002-10-02 2006-08-08 Standen Ltd. Apparatus and method for treating a tumor or the like
US7016725B2 (en) * 2001-11-06 2006-03-21 Standen Ltd. Method and apparatus for destroying dividing cells
US7599746B2 (en) 2000-02-17 2009-10-06 Standen Ltd Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
US6868289B2 (en) * 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
US6714816B1 (en) * 2000-02-22 2004-03-30 University Of South Florida Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
US7742811B2 (en) * 2000-03-13 2010-06-22 Onco Stim Implantable device and method for the electrical treatment of cancer
US8024048B2 (en) * 2000-03-13 2011-09-20 Ionix Medical Inc. Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
JP2004532654A (en) 2000-05-22 2004-10-28 マーク・アンド・カンパニー・インコーポレイテッド Drug administration system performance evaluation system and method
DE10031179A1 (en) * 2000-06-27 2002-01-31 Amaxa Gmbh Introducing active molecules into the nucleus of eukaryotic cells, useful for transfection and gene therapy, by applying controlled electrical pulse
US6914423B2 (en) 2000-09-05 2005-07-05 Cascade Microtech, Inc. Probe station
US6965226B2 (en) 2000-09-05 2005-11-15 Cascade Microtech, Inc. Chuck for holding a device under test
DE10143173A1 (en) 2000-12-04 2002-06-06 Cascade Microtech Inc Wafer probe has contact finger array with impedance matching network suitable for wide band
US6645757B1 (en) 2001-02-08 2003-11-11 Sandia Corporation Apparatus and method for transforming living cells
DE10119901A1 (en) * 2001-04-23 2002-10-24 Amaxa Gmbh Apparatus for electrophoretic transfer of biologically active molecules into cells comprises capacitors connected to high voltage sources, which discharge via power transistor into cuvette holding sample
US6733485B1 (en) 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US7127284B2 (en) * 2001-06-11 2006-10-24 Mercator Medsystems, Inc. Electroporation microneedle and methods for its use
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
KR20030012995A (en) * 2001-08-06 2003-02-14 주식회사 토이랩 Electroporator using dc power supply
WO2003052435A1 (en) 2001-08-21 2003-06-26 Cascade Microtech, Inc. Membrane probing system
AU2002360540A1 (en) * 2001-12-04 2003-06-17 University Of Southern California Method for intracellular modifications within living cells using pulsed electric fields
WO2003049806A1 (en) * 2001-12-06 2003-06-19 Bio-Rad Laboratories, Inc. Automatic electroporation optimization system
AU2003219805B2 (en) * 2002-02-15 2009-06-04 Eisai Inc. Electroporation methods for introducing bioactive agents into cells
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
EP1480720B1 (en) * 2002-03-07 2018-08-22 Inovio Pharmaceuticals, Inc. Electrode assembly for constant-current electroporation
US20030204161A1 (en) * 2002-04-25 2003-10-30 Bozidar Ferek-Petric Implantable electroporation therapy device and method for using same
US6929949B1 (en) 2002-06-14 2005-08-16 University Of South Florida Corona ion generating method and apparatus for the manipulation of molecules and biological cells
US7057404B2 (en) 2003-05-23 2006-06-06 Sharp Laboratories Of America, Inc. Shielded probe for testing a device under test
US7492172B2 (en) 2003-05-23 2009-02-17 Cascade Microtech, Inc. Chuck for holding a device under test
US6969604B1 (en) 2003-06-20 2005-11-29 Yakovenko Sergey A Electroporation chamber
US7250626B2 (en) 2003-10-22 2007-07-31 Cascade Microtech, Inc. Probe testing structure
US8500713B2 (en) * 2003-10-29 2013-08-06 Medtronic, Inc. Implantable electroporation therapy device and method for using same
US7187188B2 (en) 2003-12-24 2007-03-06 Cascade Microtech, Inc. Chuck with integrated wafer support
JP2007517231A (en) 2003-12-24 2007-06-28 カスケード マイクロテック インコーポレイテッド Active wafer probe
US20050222646A1 (en) * 2004-04-06 2005-10-06 Kai Kroll Method and device for treating cancer with modified output electrical therapy
US20050282265A1 (en) * 2004-04-19 2005-12-22 Laura Vozza-Brown Electroporation apparatus and methods
WO2005115535A2 (en) * 2004-04-23 2005-12-08 Novocure Ltd. Treating a tumor or the like with electric fields at different frequencies
EP1743030A2 (en) * 2004-05-06 2007-01-17 The Trustees of Dartmouth College Method and apparatus for bacterial transformation by electroporation with waveforms incorporating pulsed rf between 3 and 125 mhz
EP1607484B1 (en) * 2004-06-14 2014-04-02 Lonza Cologne GmbH Method and circuitry for treating biological material
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
DE202005021386U1 (en) * 2004-07-07 2007-11-29 Cascade Microtech, Inc., Beaverton Probe with a sensor with membrane suspension
WO2006031646A2 (en) 2004-09-13 2006-03-23 Cascade Microtech, Inc. Double sided probing structures
US7776373B2 (en) * 2004-11-19 2010-08-17 Eteka Llc Apparatus and method for the enhancement of food properties and food prepared therefrom
DK2345451T3 (en) * 2004-12-07 2018-04-23 Novocure Ltd Electrodes for applying an electric field in vivo over an extended period of time
JP5559460B2 (en) * 2004-12-27 2014-07-23 スタンデン・リミテッド Method for treating tumors or the like using electric fields of different orientations
SG123643A1 (en) * 2004-12-28 2006-07-26 Nanyan Polytechnic Programmable apparatus and method for optimizing and real time monitoring of gene transfection basedon user configured arbitrary waveform pulsing tra in
US7656172B2 (en) 2005-01-31 2010-02-02 Cascade Microtech, Inc. System for testing semiconductors
US7535247B2 (en) 2005-01-31 2009-05-19 Cascade Microtech, Inc. Interface for testing semiconductors
EP1741778B1 (en) * 2005-07-07 2007-12-26 Amaxa AG Procedure for the treatment of small volumes with electric current
JP2009520509A (en) 2005-10-03 2009-05-28 ノヴォキュアー・リミテッド Electric field optimization properties to increase the effect of electric fields in proliferating cells
FR2893256B1 (en) * 2005-11-14 2008-08-15 Yves Scherman GENERATOR OF ELECTRIC PULSES UNIPOLAR.
DE602006014206D1 (en) * 2006-01-03 2010-06-17 Alcon Inc SYSTEM FOR CUTTING AND REMOVING PROTEINOUS TISSUE
US20070232984A1 (en) * 2006-03-30 2007-10-04 Michael Lovell Hand-held electrical stimulation device
US8019414B2 (en) 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US7764072B2 (en) 2006-06-12 2010-07-27 Cascade Microtech, Inc. Differential signal probing system
US7723999B2 (en) 2006-06-12 2010-05-25 Cascade Microtech, Inc. Calibration structures for differential signal probing
US7403028B2 (en) 2006-06-12 2008-07-22 Cascade Microtech, Inc. Test structure and probe for differential signals
US20080012578A1 (en) * 2006-07-14 2008-01-17 Cascade Microtech, Inc. System for detecting molecular structure and events
HUE042044T2 (en) 2006-10-17 2019-06-28 Inovio Pharmaceuticals Inc Electroporation devices for electroporation of cells in mammals
DK2167194T3 (en) 2007-03-06 2017-06-19 Novocure Ltd TREATMENT OF CANCER USING ELECTROMAGNETIC FIELDS IN COMBINATION WITH PHOTODYNAMIC THERAPY
US7876114B2 (en) 2007-08-08 2011-01-25 Cascade Microtech, Inc. Differential waveguide probe
WO2009022225A1 (en) * 2007-08-14 2009-02-19 Novocure Ltd. Treating parasites with electric fields
DE102007056488A1 (en) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
DE102008016275A1 (en) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
DE102008023913A1 (en) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
CN101918566A (en) 2007-11-22 2010-12-15 Biontex实验室有限公司 By influencing the transfection results that innate immune system improves non-viral delivery system
US20110045001A1 (en) * 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
US10842555B2 (en) * 2008-08-20 2020-11-24 Prostacare Pty Ltd Catheter for treating tissue with non-thermal ablation
US8222909B2 (en) * 2008-08-22 2012-07-17 Bio-Rad Laboratories, Inc. Electroporation system with dial-in time constant
US7888957B2 (en) * 2008-10-06 2011-02-15 Cascade Microtech, Inc. Probing apparatus with impedance optimized interface
WO2010059247A2 (en) 2008-11-21 2010-05-27 Cascade Microtech, Inc. Replaceable coupon for a probing apparatus
US8319503B2 (en) 2008-11-24 2012-11-27 Cascade Microtech, Inc. Test apparatus for measuring a characteristic of a device under test
US20110118729A1 (en) * 2009-11-13 2011-05-19 Alcon Research, Ltd High-intensity pulsed electric field vitrectomy apparatus with load detection
US20110118734A1 (en) * 2009-11-16 2011-05-19 Alcon Research, Ltd. Capsularhexis device using pulsed electric fields
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
US20110144638A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Shockwave-Induced Tissue Disruption
US20110144562A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields
US20110144641A1 (en) * 2009-12-15 2011-06-16 Alcon Research, Ltd. High-Intensity Pulsed Electric Field Vitrectomy Apparatus
JP4713671B1 (en) * 2010-01-22 2011-06-29 ネッパジーン株式会社 Foreign gene transfer by electroporation
ES2413557T3 (en) * 2010-06-22 2013-07-16 Lonza Cologne Gmbh Procedure and arrangement of electrodes to treat adherent cells
US8546979B2 (en) 2010-08-11 2013-10-01 Alcon Research, Ltd. Self-matching pulse generator with adjustable pulse width and pulse frequency
EP2621522A2 (en) 2010-09-27 2013-08-07 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012158132A1 (en) 2011-05-18 2012-11-22 Eteka Llc Apparatus for the enhancement of food properties by electroporation or pulsed electric fields
CN103239734B (en) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 For preventing and/or treating the vaccine of respiratory syncytial virus infection
JP2013198637A (en) * 2012-03-26 2013-10-03 Toshiyuki Moriizumi Power source for electroporator
EP3808844A1 (en) 2012-07-25 2021-04-21 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
US20160279434A1 (en) * 2012-11-14 2016-09-29 International Scientific Pty Ltd A device, system, method, computer program and data signal for the control of a transdermal delivery device
MX364732B (en) 2012-12-13 2019-05-06 Univ Pennsylvania Wt1 vaccine.
EP3003342B1 (en) 2013-05-30 2022-01-26 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
JP6649252B2 (en) 2013-10-07 2020-02-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Vaccine with interleukin-33 as adjuvant
WO2015070027A1 (en) 2013-11-07 2015-05-14 University Of Southern California Use of ikk epsilon inhibitors to activate nfat and t cell response
WO2015073291A1 (en) 2013-11-14 2015-05-21 The Trustees Of The University Of Pennsylvania Hiv-1 env dna vaccine plus protein boost
CA2932055A1 (en) 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Mers-cov vaccine
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
US9708597B2 (en) * 2014-01-17 2017-07-18 General Electric Company Electric pulse generation systems using capacitive coupling
US9162189B1 (en) 2014-05-30 2015-10-20 Pall Corporation Membrane comprising self-assembled block copolymer and process for producing the same by spin coating (Ia)
US9593219B2 (en) 2014-05-30 2017-03-14 Pall Corporation Membrane comprising self-assembled block copolymer and process for producing the same by spin coating (IIa)
US9163122B1 (en) 2014-05-30 2015-10-20 Pall Corporation Self-assembling polymers—II
US9598543B2 (en) 2014-05-30 2017-03-21 Pall Corporation Self-assembled structure and membrane comprising block copolymer and process for producing the same by spin coating (VIa)
US9593218B2 (en) 2014-05-30 2017-03-14 Pall Corporation Self-assembled structure and membrane comprising block copolymer and process for producing the same by spin coating (IIIa)
US9592477B2 (en) 2014-05-30 2017-03-14 Pall Corporation Membrane comprising self-assembled block copolymer and process for producing the same by hybrid casting (Ib)
US9765171B2 (en) 2014-05-30 2017-09-19 Pall Corporation Self-assembling polymers—V
US9193835B1 (en) 2014-05-30 2015-11-24 Pall Corporation Self-assembling polymers—IV
US9616395B2 (en) 2014-05-30 2017-04-11 Pall Corportaion Membrane comprising self-assembled block copolymer and process for producing the same by spray coating (Ic)
US9604181B2 (en) 2014-05-30 2017-03-28 Pall Corporation Membrane comprising self-assembled block copolymer and process for producing the same by spray coating (IIc)
US9592476B2 (en) 2014-05-30 2017-03-14 Pall Corporation Membrane comprising self-assembled block copolymer and process for producing the same by hybrid casting (IIb)
US9169361B1 (en) 2014-05-30 2015-10-27 Pall Corporation Self-assembling polymers—VI
US9328206B2 (en) 2014-05-30 2016-05-03 Pall Corporation Self-assembling polymers—III
US9593217B2 (en) 2014-05-30 2017-03-14 Pall Corporation Self-assembled structure and membrane comprising block copolymer and process for producing the same by spin coating (Va)
US9962662B2 (en) 2014-06-30 2018-05-08 Pall Corporation Fluorinated polymer and use thereof in the preparation of hydrophilic membranes (vi)
US9254466B2 (en) 2014-06-30 2016-02-09 Pall Corporation Crosslinked cellulosic membranes
US9718924B2 (en) 2014-06-30 2017-08-01 Pall Corporation Hydrophilic block copolymers and membranes prepared therefrom (II)
US9303133B2 (en) 2014-06-30 2016-04-05 Pall Corporation Hydrophilic membranes and method of preparation thereof (IV)
US9260569B2 (en) 2014-06-30 2016-02-16 Pall Corporation Hydrophilic block copolymers and method of preparation thereof (III)
US9309367B2 (en) 2014-06-30 2016-04-12 Pall Corporation Membranes comprising cellulosic material and hydrophilic block copolymer (V)
US9394407B2 (en) 2014-06-30 2016-07-19 Pall Corporation Hydrophilic block copolymers and membranes prepared therefrom (I)
KR20230145241A (en) 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines having an antigen and interleukin-21 as an adjuvant
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
US11116838B2 (en) 2015-01-29 2021-09-14 The Trustees Of The University Of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
US11160976B2 (en) 2015-02-17 2021-11-02 Eunsung Global Corp. Skin treatment device using needles
KR101740950B1 (en) 2015-02-17 2017-06-15 주식회사 은성글로벌 Skin therapy apparatus with needle
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
CN109536474A (en) 2015-06-18 2019-03-29 布罗德研究所有限公司 Reduce the CRISPR enzyme mutant of undershooting-effect
MX2018001511A (en) 2015-08-04 2018-08-01 Univ Duke Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same.
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
CN109152818B (en) 2015-12-21 2023-06-23 杜克大学 Polymer conjugates with reduced antigenicity and methods of use thereof
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3445848A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Novel crispr enzymes and systems
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
AU2017257191B2 (en) 2016-04-29 2023-08-10 Inovio Pharmaceuticals, Inc. The in vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
EP3515928A4 (en) 2016-09-23 2020-04-01 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US10376495B2 (en) 2016-11-23 2019-08-13 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
JP7114094B2 (en) 2016-12-22 2022-08-08 オハイオ・ステイト・イノベーション・ファウンデーション Interpenetrating microstructures for nanochannel-based cargo delivery
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US10813935B2 (en) 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer
US10272052B2 (en) 2017-02-24 2019-04-30 University Of South Florida Compositions and methods for the treatment of tauopathies
US11318155B2 (en) 2017-02-24 2022-05-03 University Of South Florida Hsp90 activator Aha1 drives production of pathological tau aggregates
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
JP6518971B2 (en) * 2017-05-12 2019-05-29 株式会社ベックス Electroporator power supply
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3625343A1 (en) 2017-05-18 2020-03-25 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US20210093667A1 (en) 2017-06-26 2021-04-01 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3684397A4 (en) 2017-09-21 2021-08-18 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
EP3716875A4 (en) 2017-11-27 2021-08-25 Prostacare Pty Ltd An apparatus and a method for the treatment of a prostatic disease
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
WO2019168949A1 (en) 2018-02-28 2019-09-06 Prostacare Pty Ltd System for managing high impedance changes in a non-thermal ablation system for bph
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020010388A1 (en) * 2018-07-13 2020-01-16 International Scientific Pty Ltd A method and apparatus for user-controlled or practitioner-prescribed transdermal, intradermal or transappendageal delivery of therapeutic, cosmetic or skin care ingredients
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US20210163944A1 (en) 2018-08-07 2021-06-03 The Broad Institute, Inc. Novel cas12b enzymes and systems
US20210355522A1 (en) 2018-08-20 2021-11-18 The Broad Institute, Inc. Inhibitors of rna-guided nuclease activity and uses thereof
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. Arc-based capsids and uses thereof
US20220401460A1 (en) 2018-10-10 2022-12-22 Dana-Farber Cancer Institute, Inc. Modulating resistance to bcl-2 inhibitors
US20220411783A1 (en) 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
JP7121419B2 (en) * 2018-10-29 2022-08-18 株式会社ベックス Bubble ejection method, bubble ejection power supply device, and bubble ejection device
WO2020102610A1 (en) 2018-11-14 2020-05-22 The Broad Institute, Inc. Crispr system based droplet diagnostic systems and methods
WO2020124050A1 (en) 2018-12-13 2020-06-18 The Broad Institute, Inc. Tiled assays using crispr-cas based detection
AU2019406778A1 (en) 2018-12-17 2021-07-22 Massachusetts Institute Of Technology Crispr-associated transposase systems and methods of use thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
JP7377561B2 (en) 2019-03-14 2023-11-10 株式会社ベックス Method for introducing substances into protoplasts or algae by electroporation, and power supply device for electroporator
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
US20220195514A1 (en) 2019-03-29 2022-06-23 The Broad Institute, Inc. Construct for continuous monitoring of live cells
WO2020206036A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Novel nucleic acid modifier
WO2020206046A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Methods and compositions for cell therapy
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
US20220243178A1 (en) 2019-05-31 2022-08-04 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CN114340723A (en) * 2019-09-02 2022-04-12 米拉伊医疗有限公司 Electroporation device and method
TW202128775A (en) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties
MX2022010460A (en) 2020-02-25 2022-09-19 Inovio Pharmaceuticals Inc Vaccines against coronavirus and methods of use.
WO2021231925A1 (en) 2020-05-14 2021-11-18 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
AU2021289600A1 (en) 2020-06-12 2023-01-19 University Of Rochester Encoding and expression of ACE-tRNAs
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (en) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1 binding polypeptides
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3607689A (en) * 1967-10-17 1971-09-21 Inoue K Power supply for large-surface electrochemical machining
US4063146A (en) * 1975-05-22 1977-12-13 Reliance Electric Company Digital firing control for a converter
US4408268A (en) * 1982-08-09 1983-10-04 General Electric Company Pulse modulated electronic voltage controller with smooth voltage output
IT1181297B (en) * 1984-04-19 1987-09-23 Icm Italiana Cost Metalmecc DEVICE FOR THE AUTOMATIC CONTROL OF THE FEEDING OF A TUBULAR WIRE, IN PARTICULAR IN PRECIOUS MATERIAL IN THE GOLDSMITH INDUSTRY
US4713740A (en) * 1984-07-27 1987-12-15 Sms Advanced Power, Inc. Switch-mode power supply
US4663292A (en) * 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4946793A (en) * 1986-05-09 1990-08-07 Electropore, Inc. Impedance matching for instrumentation which electrically alters vesicle membranes
US4750100A (en) * 1986-06-06 1988-06-07 Bio-Rad Laboratories Transfection high voltage controller
US5098843A (en) * 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5186800A (en) * 1988-04-18 1993-02-16 Bio-Rad Laboratories, Inc. Electroporation of prokaryotic cells
US4885943A (en) * 1988-05-11 1989-12-12 Hydro-Craft, Inc. Electronic flowmeter system and method
US5047007A (en) * 1989-12-22 1991-09-10 Medtronic, Inc. Method and apparatus for pulsed iontophoretic drug delivery
BE1004328A3 (en) * 1990-05-16 1992-11-03 Scient Equipment Design & Dev METHOD AND DEVICE FOR LIVING CELLS permeabilization.
US5097403A (en) * 1991-02-11 1992-03-17 Astec International Ltd. Current sensing synchronous rectifier apparatus
US5169384A (en) * 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
US5545130A (en) * 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5507724A (en) * 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5315498A (en) * 1992-12-23 1994-05-24 International Business Machines Corporation Apparatus providing leading leg current sensing for control of full bridge power supply
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5422272A (en) * 1993-07-14 1995-06-06 Andrew A. Papp Improvements to apparatus and method for electroporation
IL108775A (en) * 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
US5642035A (en) * 1994-06-16 1997-06-24 Bio-Rad Laboratories Transfection high-voltage controller
US5542967A (en) * 1994-10-06 1996-08-06 Ponizovsky; Lazar Z. High voltage electrical apparatus for removing ecologically noxious substances from gases
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same

Also Published As

Publication number Publication date
JP2001503208A (en) 2001-03-06
JP3963955B2 (en) 2007-08-22
EP0925647A1 (en) 1999-06-30
KR100420731B1 (en) 2004-03-02
DE69711893T2 (en) 2002-11-14
KR20000035966A (en) 2000-06-26
US6096020A (en) 2000-08-01
US5869326A (en) 1999-02-09
ES2175343T3 (en) 2002-11-16
ATE216155T1 (en) 2002-04-15
DE69711893D1 (en) 2002-05-16
EP0925647B1 (en) 2002-04-10
WO1998010515A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
CA2261703A1 (en) Electroporation employing user-configured pulses
EP0788392B1 (en) Electroporetic gene and drug therapy by induced electric fields
US6150148A (en) Electroporation apparatus for control of temperature during the process
Weaver Electroporation of biological membranes from multicellular to nano scales
US6027488A (en) Flow-through electroporation system for ex vivo gene therapy
EP0785987B1 (en) Flow through electroporation apparatus and method
US6778853B1 (en) Electroporation device
US20050277868A1 (en) Electroporation Device and Method for Delivery to Ocular Tissue
CA2937911A1 (en) Method and apparatus for intracellular and intercellular delivery of molecules, drugs, vaccines and the like
US20020103515A1 (en) Magnetic fields for the treatment of cancer and to assist in nerve regeneration
EP4230718A2 (en) An electroporation apparatus and method
US6937890B2 (en) Nonpenetrating electroporation device
CA2355051C (en) Nonpenetrating electroporation device
AU2001281911A1 (en) Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current
DK1216076T3 (en) A method and apparatus for stimulating / modulating biochemical processes using pulsed electromagnetic fields
JP4566496B2 (en) Electroporation element and electroporation method
Teissié Electrically mediated gene delivery: basic and translational concepts
Jamil et al. Optimization of pulse duration parameter for hela cells growth rate
AU2004201004B2 (en) Nonpenetrating electroporation device
Teissie Chapter Electrically Mediated Gene Delivery: Basic and Translational Concepts
Rey et al. Feasibility study for focusing electric fields to mediate in vitro drug and gene delivery
Heller et al. Electroporation device
BG63712B1 (en) Method and apparatus for electrochemiotherapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued